EP4704812A1 - A pharmaceutical composition comprising emetine and mitoxantrone for the prevention or treatment of mammary gland cancer and a liposome containing this composition - Google Patents
A pharmaceutical composition comprising emetine and mitoxantrone for the prevention or treatment of mammary gland cancer and a liposome containing this compositionInfo
- Publication number
- EP4704812A1 EP4704812A1 EP24741025.1A EP24741025A EP4704812A1 EP 4704812 A1 EP4704812 A1 EP 4704812A1 EP 24741025 A EP24741025 A EP 24741025A EP 4704812 A1 EP4704812 A1 EP 4704812A1
- Authority
- EP
- European Patent Office
- Prior art keywords
- emetine
- mitoxantrone
- liposomes
- concentration
- composition
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/13—Amines
- A61K31/135—Amines having aromatic rings, e.g. ketamine, nortriptyline
- A61K31/136—Amines having aromatic rings, e.g. ketamine, nortriptyline having the amino group directly attached to the aromatic ring, e.g. benzeneamine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/47—Quinolines; Isoquinolines
- A61K31/4738—Quinolines; Isoquinolines ortho- or peri-condensed with heterocyclic ring systems
- A61K31/4745—Quinolines; Isoquinolines ortho- or peri-condensed with heterocyclic ring systems condensed with ring systems having nitrogen as a ring hetero atom, e.g. phenantrolines
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
- A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
- A61K47/24—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing atoms other than carbon, hydrogen, oxygen, halogen, nitrogen or sulfur, e.g. cyclomethicone or phospholipids
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/10—Dispersions; Emulsions
- A61K9/127—Synthetic bilayered vehicles, e.g. liposomes or liposomes with cholesterol as the only non-phosphatidyl surfactant
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/10—Dispersions; Emulsions
- A61K9/127—Synthetic bilayered vehicles, e.g. liposomes or liposomes with cholesterol as the only non-phosphatidyl surfactant
- A61K9/1271—Non-conventional liposomes, e.g. PEGylated liposomes or liposomes coated or grafted with polymers
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K2121/00—Preparations for use in therapy
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K2300/00—Mixtures or combinations of active ingredients, wherein at least one active ingredient is fully defined in groups A61K31/00 - A61K41/00
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Veterinary Medicine (AREA)
- Medicinal Chemistry (AREA)
- Public Health (AREA)
- Pharmacology & Pharmacy (AREA)
- Animal Behavior & Ethology (AREA)
- Epidemiology (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Dispersion Chemistry (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Organic Chemistry (AREA)
- Molecular Biology (AREA)
- Engineering & Computer Science (AREA)
- Oil, Petroleum & Natural Gas (AREA)
- Biophysics (AREA)
- Medicinal Preparation (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Abstract
The description of the invention discloses a pharmaceutical composition comprising emetine at a concentration of not less than 0.01 μM and mitoxantrone at a concentration of not less than 0.003 μM for use in the treatment of mammary gland cancer and a liposome comprising at least three lipids including DPPC, DSPE-PEG(2000)amine and cholesterol containing the composition.
Description
A PHARMACEUTICAL COMPOSITION COMPRISING EMETINE AND MITOXANTRONE FOR THE PREVENTION OR TREATMENT OF MAMMARY GLAND CANCER AND A LIPOSOME CONTAINING THIS COMPOSITION
The object of the invention is a pharmaceutical composition for the prevention or treatment of cancer and diseases resulting from excessive cell proliferation, in particular mammary gland cancer, and a liposome containing the composition.
Cancer treatment can be local or systemic. Local treatment usually consists of removing the tumour or using radiotherapy. Systemic treatment affects other cells in the body in addition to the tumour cells. Such methods include chemotherapy, hormone therapy or targeted treatment, which involves the administration of intravenous or oral drugs that are tailored to the progression of the disease. Other methods of cancer treatment are also known from the state of the art.
Liposomes are commonly used as carriers in chemotherapy with cytostatic drugs, due to their ability to transport these drugs to their target sites in the body. They are spherical vesicles made up of one or more phospholipid bilayers surrounding a liquid interior. The lipid composition of liposomes is crucial for their stability and physicochemical properties. The choice of suitable lipids and their ratio affects the size, shape, stability and surface properties of liposomes. The size and surface properties of liposomes, on the other hand, are crucial for their bioavailability, stability and their selectivity of drug delivery to target tissues and cells (https://doi.Org/10.1016/j.addr.2012.09.037). Polyethylene glycol (PEG) is commonly used in the surface modification of liposomes to increase their stability in plasma, improve bioavailability and prolong circulation time (DOI: 10.1016/j.jconrel.2013.07.026). In addition, the chain length of polyethylene glycol (PEG) can affect the site of drug accumulation in the human body and
the targeting efficiency of a therapy (10.1016/j.biomaterials.2011 .04.082). The most commonly used polyethylene glycol for modifying liposomes is a polymer terminated with a terminal methoxyl group (-O-CH3 ), the so-called MPEG. Other modifications such as a terminal amino group (-NH2) or a carboxyl group (-COOH) are usually used as intermediates for further modification with proteins or other cell homing molecules (https://doi.org/10.1038/s41598-021-86860-5) and their potential to generate surface charge in the changing tumour environment has so far been neglected. On the other hand, it is known that the surface charge of liposomes can influence where they accumulate in the body and, in particular, their accumulation in tumour tissues. Studies show that positively charged liposomes have better accumulation and penetration of the carrier in tumour tissues and better cellular uptake compared to inert and negatively charged nanoparticles
(https://doi.Org/10.1016/j.nantod.2016.04.008). The presence of a positive charge on the surface of liposomes is therefore crucial in ensuring efficient and specific transport into tumour tissues.
The essence of the pharmaceutical composition solution according to the invention is a composition comprising emetine at a concentration of not less than 0.003 pM and mitoxantrone at a concentration of not less than 0.01 pM for use in the treatment of mammary gland cancer.
Favourably, the concentration ratio of emetine and mitoxantrone is between 1 :3 and 1 :5.
The essence of the solution according to the invention for the modified liposome is that the liposome is composed of at least three lipids, including DPPC (1 ,2-dipalmitoyl-sn-glycero-3-phosphocholine) in an amount of 48.6 to 70.7% by weight, cholesterol in an amount of 18.3 to 18,6% by weight, DSPE-PEG(2000)amine (ammonium salt of 1 ,2- distearoyl-sn-glycero-3-phosphoethanolamine-N -[amino(polyethylene
glycol)-2000]) in an amount of 10.6 to 10.7% by weight and contains emetine in a concentration of not less than 0.003 pM and mitoxantrone in a concentration of not less than 0.01 pM.
Favourably, the concentration ratio of emetine and mitoxantrone is between 1 :3 and 1 :5.
The main advantage of the solutions according to the inventions is that the composition used has a dual action, which leads to the arrest of growth or death of the cell by a synergistic combination of two mechanisms that would generally not be targeted by a single inhibitor, leading to the arrest of growth or death of the cancer cell. The synergism that occurs with emetine and mitoxantrone allows the use of much lower doses of the substances and limits the side effects of their use. The main advantage of modified liposomes as carriers for the compositions is that due to the positive charge generated by the presence of the terminal amino group, there is effective accumulation of the carrier with the drug in solid tumours, and thus anticancer therapy with these drugs is much more effective. This has been demonstrated in in vitro studies for emetine- and mitoxantrone-loaded nanoparticles. In the case of these studies, a 3-4 times higher treatment efficacy was achieved, resulting in tumour shrinkage at twice the dose compared to the free drugs.
The developed carriers allow emetine loading of up to above 95% for a drug to lipid ratio of 0.1 , which is twice the value reported in the literature. At higher initial drug concentrations, liposomes allow up to four times higher drug to lipid ratios than liposomes reported in the publications. The reason for such good loading is the specific lipid structure containing a terminal amino group in the polyethylene glycol molecule.
These carriers ensure that emetine is loaded inside the liposomes and not deposited on the surface, as indicated by the lack of significant changes in the Zeta potential of the liposomes after the drug loading process. Additional studies of emetine-loaded liposomes in the presence of human and rat
albumin confirm the lack of sudden drug release under in vitro test conditions.
These carriers also allow for the binding of emetine in the presence of other drugs such as mitoxantrone without a drastic decrease in the %EE encapsulation value of emetine. The presence of a 5-fold excess of mitoxantrone (a drug from the anthracycline group) preserves the %EE of emetine at 95-99%, whereas literature values of liposomal carriers containing an anthracycline-emetine mixture at these concentrations indicate a decrease in %EE to values lower than 30%.
The carriers also provide a significant reduction in the toxicity of emetine encapsulated in liposomes compared to free emetine. They indicate much lower LC50 values for drugs encapsulated in carriers. The LC50 value calculated for emetine encapsulated in a liposome is 12-fold higher after 24 h of dosing than the value calculated for the free drug. This creates the possibility of significantly reducing the toxicity of this drug and thus enabling the use of this drug in anticancer therapies.
The solutions according to the inventions are illustrated by the following fabrication examples and drawings, where Fig. 1 .1 shows an example of the size distribution of the hydrodynamic radii of nanoCombo 6.2 liposomes after synthesis and purification (see fabrication description for details), measured by dynamic light scattering. Sample diluted 10 times; Fig. 1.2 - Example of size distribution of hydrodynamic radii of nanoCombo 6.3 liposomes after synthesis and purification, measured by dynamic light scattering. Fig. 1.3 - exemplary size distribution of hydrodynamic radii of nanoCombo 6.4 liposomes after synthesis and purification, measured by dynamic light scattering; Fig.1.4. - Example size distribution of hydrodynamic radii of nanoCombo 6.6 liposomes after synthesis and purification, measured by dynamic light scattering; Fig.1.5. - Example Zeta potential distribution of nanoCombo 6.2 liposomes after synthesis and purification, measured by dynamic light scattering; Fig.1..6. - Example Zeta
potential distribution of nanoCombo 6.3 liposomes after synthesis and purification, measured by dynamic light scattering; Fig. 1.7. - Example Zeta potential distribution of nanoCombo 6.4 liposomes after synthesis and purification, measured by dynamic light scattering; Fig. 1.8. - Example Zeta potential distribution of nanoCombo 6.6 liposomes after synthesis and purification, measured by dynamic light scattering; Fig. 2.1 - Growth kinetics of CAL-148 human lung cancer tumours in mice treated with Emetine, Mitoxantrone and their combinations at a concentration ratio of 1 :5; Fig. 2.2
- Growth kinetics of CAL-148 human lung cancer tumours in mice treated with Emetine, Mitoxantrone and their combinations at a concentration ratio of 1 :3; Fig. 3.1 - Growth kinetics of CAL-51 human lung cancer tumours in mice treated with Emetine, Mitoxantrone and their combinations at a concentration ratio of 1 :5; Fig. 3.2 - Growth kinetics of CAL-51 human lung cancer tumours in mice treated with Emetine, Mitoxantrone and their combinations at a concentration ratio of 1 :3; Fig. 4.1 - Growth kinetics of Hs578T human lung cancer tumours in mice treated with Emetine, Mitoxantrone and their combinations at a concentration ratio of 1 :5; Fig. 4.2
- Growth kinetics of Hs578T human lung cancer tumours in mice treated with Emetine, Mitoxantrone and their combinations at a concentration ratio of 1 :3; Fig. 5.1 - Growth kinetics of MDAMB231 human lung cancer tumours in mice treated with Emetine, Mitoxantrone and their combinations at a concentration ratio of 1 :5; Fig. 5.2 - Growth kinetics of MDAMB231 human lung cancer tumours in mice treated with Emetine, Mitoxantrone and their combinations at a concentration ratio of 1 :3; Fig. 6.1 - Growth kinetics of MDAMB453 human lung cancer tumours in mice treated with Emetine, Mitoxantrone and their combinations at a concentration ratio of 1 :5; Fig. 6.2
- Growth kinetics of MDAMB453 human lung cancer tumours in mice treated with Emetine, Mitoxantrone and their combinations at a concentration ratio of 1 :3;
Example I
Synthesis and physicochemical parameters of liposomes
A lipid solution in 99.8% ethanol with a total lipid concentration of 100mg/ml was prepared with the composition: DPPC/Cholesterol/DSPE- PEG(2000)NH2 in molar fractions of 0.65/0.32/0.026 and mass fractions of 0.70650/0.18607/0.1O743.The whole was heated for 15 minutes in a water bath at 60°C. Subsequently, a solution (NH )42 SO4 , at a concentration of 350mM in deionised water, was prepared in sterile urea. The solution was filtered using sterile syringe filters with a hydrophilic PTFE membrane with a pore diameter of 0.22 pm. The pH of the solution was titrated with 0.3M HCL solution until a pH of 5.3 was obtained.
Liposomes were prepared using a NanoAssemblr IGNITE microfluidic device™ with an NxGen cartridge. Flow parameters set: volume ratio of aqueous phase to organic phase 9:1 ; total flow rate 5ml/min, final volume of reaction mixture 9.05ml; initial loss 0.9ml; final loss 0.05ml. Six batches of liposomes were prepared. Liposomes were dialysed using MWCO 100kD pore diameter tubular dialysis membranes with a volume of 10ml, which were conditioned for 20 minutes each time in solutions of, respectively: 10% ethanol, deionised water and PBS buffer, pH 8.5.
A 5-fold PBS buffer concentrate pH 7.4 was prepared by dissolving 20 g NaCI, 3.6 g Na2 HPO4 (anhydrous), 0.775 g NaH2 PO X2H42 O (dihydrate), 0.5 g KCI in 0.5 L deionised water (milliQ). It was stirred on a magnetic stirrer for 30 min. The buffer was then diluted 5-fold and 0.1 M NaOH was added until a pH of 8.5 was obtained.
Liposomes were dialysed in a refrigerator (4°C) for 14 h, changing the external buffer after 2h and 6h.
Subsequently, starting solutions of emetine hydrochloride at 50mg/ml and mitoxantrone dihydrochloride in DMSO were prepared. Then, liposomes after dialysis in PBS at pH 8.5 were added with the emetine hydrochloride stock solution according to Table 1 and mixed. Mitoxantrone dihydrochloride stock solution was then added according to Table 1 and mixed. The bottle
was tightly closed and heated in a water bath at 60°C for 15 minutes. After removal from the water bath, the liposomes were allowed to cool for 30 minutes. The vessel with liposomes was protected from light. The liposomes were then separated on a Sephadex G-25 packed chromatography column and the encapsulation rate (loading rate) of the drugs into the liposomes was determined by UV-Vis spectroscopy against a calibration curve using the principle of additivity of absorbance. Drug concentrations in liposomal fractions were determined by UV-Vis spectroscopy against calibration curves by dissolving 100uL of liposome sample in 850uL ethanol and 50uL 0.3M HCI (concentrations shown in Table 1). Hydrodynamic diameters and polydispersity indexes (PDI) and Zeta potentials of the nanoparticles were measured. All data are summarised in Table_1. Example distributions of hydrodynamic diameters with PDI coefficients and example distributions of Zeta potentials of the produced liposomes are summarised in Fig. 1.1 - Fig. 1.8.
Table 1 Physicochemical parameters of liposomes loaded with emetine hydrochloride (EM) and mitoxantrone dihydrochloride (MX) after synthesis.
Example II
Exploring synergies
The assay used emetine and mitoxantrone, which were dissolved in water and stored as 50mM stock solutions at -80°C. Cell lines were used in the assay as shown in Table 2.1 .
Table 2.1 List of cell lines detailing their origin
Cells were thawed from ampoules stored in liquid nitrogen and cultured in petri dishes in the appropriate culture medium according to Table 2.2, in a humidified 5% CO2 atmosphere at 37°C. Cells were passaged twice weekly using EDTA-Trypsin solution, pH 8. Counted cells with a viability of at least 90% as assessed with Trypan-Blue solution were used for anti-proliferation assays.
Table 2.2 List of cell lines and their corresponding culture medium
Twenty-four hours before the addition of the test compounds/combinations, cells were seeded into 384-well plates at 50pL/well and a density of 103 cells/well, in the appropriate culture medium. After incubation overnight, cells were treated with different concentrations of compounds or combinations of compounds mixed at different molar ratios (described in the tables summarising the individual results, with a dilution factor of 3.16x. Solutions of the compounds were diluted in the test medium - RPMI-1640 and Opti-MEM in a 1 :1 ratio, and the medium was supplemented with 2 mM glutamine and 5% fetal bovine serum FBS. After 72h, colourimetric evaluation of cell growth was performed by SRB. Cells were fixed for 1 h with cold 25% (w/v) trichloroacetic acid (TCA) solution, washed five times with tap water, and stained with 0.4% (v/v) sulforhodamine B (SRB, solution in 1 % (v/v) acetic acid) for 30 min. Unbound dye was removed by washing the plates (4x) in 1 % (v/v) acetic acid, and the protein-bound dye was extracted with 10 mM unbuffered Tris base and the optical density (A = 540 pM) was determined in a BioTek Synergy H4 Hybrid computer microplate reader (BioTek Instruments USA). The entire washing/staining procedure was performed using a BioTek EL406 washing station (BioTek Instruments USA). The raw absorbance results were analysed in Microsoft Excel software using the formula: 100
Where:
%Zahlnh - inhibition of proliferation
Am - absorbance of wells without cells (medium)
Ak - absorbance of control wells (cells treated with pure culture medium) Ap - absorbance of wells treated with compounds
The proliferation inhibition data were then used to calculate the IC50 - the concentration of the test compound that inhibits the proliferation of 50% of the tumour cell population, calculated using the GraphPadPrism 7.0 nonlinear model [Inhibitor] vs. response - Variable slope (four parameters). Each compound at the indicated concentrations was tested in triplicate in one experiment. Each experiment was repeated three times. The results obtained are presented in Tables 3.1 - 7.2 and Figs. 2.1 - 6.2.
Table 3.1 Inhibition of cell profiling of CAL148 lines for individual concentrations of Emetine, Mitoxantrone and their combinations in a 1 :5 ratio in free and nanoparticle form including standard deviation
Table 3.2 Inhibition of cell profiling of CAL148 lines for individual concentrations of Emetine, Mitoxantrone and their combinations in a 1 :3 ratio in free and nanoparticle form including standard deviation
Table 4.1 Inhibition of CAL51 cell profiling for individual concentrations of Emetine, Mitoxantrone and their combinations in a 1 :5 ratio in free and nanoparticle form including standard deviation
Table 4.2 Inhibition of CAL51 line cell profiling for individual concentrations of Emetine, Mitoxantrone and their combinations in a 1 :3 ratio in free and nanoparticle form including standard deviation
Table 5.1 Inhibition of cell profiling of line Hs578T for individual concentrations of Emetine, Mitoxantrone and their combinations in a 1 :5 ratio in free and nanoparticle form including standard deviation
Table 5.2 Inhibition of cell profiling of line Hs578T for individual concentrations of Emetine, Mitoxantrone and their combinations in a 1 :3 ratio in free and nanoparticle form including standard deviation
Table 6.1 Inhibition of cell profiling of MDAMB231 line for individual concentrations of Emetine, Mitoxantrone and their combinations in a 1 :5 ratio in free and nanoparticle form including standard deviation
Table 6.2 Inhibition of cell profiling of MDAMB231 line for individual concentrations of Emetine, Mitoxantrone and their combinations in a 1 :3 ratio in free and nanoparticle form including standard deviation
Table 7.1 Inhibition of cell profiling of MDAMB453 line for individual concentrations of Emetine, Mitoxantrone and their combinations in 1 :5 ratio in free and nanoparticle form including standard deviation
Table 7.2 Inhibition of cell profiling of MDAMB453 line for individual concentrations of Emetine, Mitoxantrone and their combinations in 1 :3 ratio in free and nanoparticle form including standard deviation
Mobile line: MDAMB453
Claims
1 . Pharmaceutical composition consisting of emetine at a concentration of not less than 0.01 pM and mitoxantrone at a concentration of not less than 0.003 pM for the treatment of mammary gland cancer.
2. The composition according to claim. 1, characterised in that the concentration ratio of emetine and mitoxantrone is from 1 :3 to 1 :5.
3. A liposome characterised in that it is composed of at least three lipids, including DPPC (1 ,2-dipalmitoyl-sn-glycero-3-phosphocholine) in an amount of 48.6 to 70.7% by weight, cholesterol in an amount of 18.3 to 18.6% by weight, DSPE-PEG(2000)amine (ammonium salt of 1 ,2- distearoyl-sn-glycero-3-phosphoethanolamine-N [amino(polyethylene glycol)-2000]) in an amount of 10.6 to 10.7% by weight and contains emetine in a concentration of not less than 0.01 pM and mitoxantrone in a concentration of not less than 0.003 pM
4. The liposome according to claim 3 characterized in that a concentration ratio of emetine and mitoxantrone of 1 :3 to 1 :5.
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| PL444723A PL247852B1 (en) | 2023-05-03 | 2023-05-03 | Pharmaceutical composition for use in the prevention or treatment of neoplastic diseases and diseases resulting from excessive cell proliferation, and liposome containing said composition |
| PCT/PL2024/000022 WO2024228631A1 (en) | 2023-05-03 | 2024-05-03 | A pharmaceutical composition comprising emetine and mitoxantrone for the prevention or treatment of mammary gland cancer and a liposome containing this composition |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| EP4704812A1 true EP4704812A1 (en) | 2026-03-11 |
Family
ID=91898949
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| EP24741025.1A Pending EP4704812A1 (en) | 2023-05-03 | 2024-05-03 | A pharmaceutical composition comprising emetine and mitoxantrone for the prevention or treatment of mammary gland cancer and a liposome containing this composition |
Country Status (5)
| Country | Link |
|---|---|
| EP (1) | EP4704812A1 (en) |
| CN (1) | CN121443272A (en) |
| IL (1) | IL324421A (en) |
| PL (1) | PL247852B1 (en) |
| WO (1) | WO2024228631A1 (en) |
Family Cites Families (5)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN104971044A (en) * | 2015-02-14 | 2015-10-14 | 吉林大学 | Mitoxantrone estrogen targeting PEG-modified liposome and applications thereof |
| AU2021218871B2 (en) * | 2020-02-10 | 2024-04-11 | Cspc Zhongqi Pharmaceutical Technology (Shijiazhuang) Co., Ltd. | Use of mitoxantrone hydrochloride liposome for treating breast cancer |
| CN114053436A (en) * | 2020-07-29 | 2022-02-18 | 深圳华润九创医药有限公司 | Application of mitoxantrone preparation in preparation of medicine for diagnosis and treatment of breast cancer |
| PL245991B1 (en) * | 2021-01-13 | 2024-11-18 | Bs Biotechna Spolka Z Ograniczona Odpowiedzialnoscia | Pharmaceutical composition for use in the treatment of breast cancer |
| PL249473B1 (en) * | 2021-08-14 | 2026-04-27 | Bs Biotechna Spółka Z Ograniczoną Odpowiedzialnością | Cationic liposome binding and stabilizing RNA, its use as a drug carrier and in gene therapy, and method of loading the liposome with emetine |
-
2023
- 2023-05-03 PL PL444723A patent/PL247852B1/en unknown
-
2024
- 2024-05-03 EP EP24741025.1A patent/EP4704812A1/en active Pending
- 2024-05-03 IL IL324421A patent/IL324421A/en unknown
- 2024-05-03 CN CN202480044869.8A patent/CN121443272A/en active Pending
- 2024-05-03 WO PCT/PL2024/000022 patent/WO2024228631A1/en not_active Ceased
Also Published As
| Publication number | Publication date |
|---|---|
| IL324421A (en) | 2026-01-01 |
| WO2024228631A1 (en) | 2024-11-07 |
| CN121443272A (en) | 2026-01-30 |
| PL247852B1 (en) | 2025-09-08 |
| PL444723A1 (en) | 2024-11-04 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| US9931418B2 (en) | Compositions for the delivery of RNA and drugs into cells | |
| Cai et al. | Aperture modulation of isoreticular metal organic frameworks for targeted antitumor drug delivery | |
| US10087442B2 (en) | Polycation-functionalized nanoporous silicon carrier for systemic delivery of gene silencing agents | |
| López-Méndez et al. | Nanomedicine for autophagy modulation in cancer therapy: a clinical perspective | |
| TWI619496B (en) | Pharmaceutical composition of hydrophobic camptothecin derivative | |
| WO2012009448A2 (en) | Cationic polymer coated mesoporous silica nanoparticles and uses thereof | |
| Cao et al. | Lipid core-shell nanoparticles co-deliver FOLFOX regimen and siPD-L1 for synergistic targeted cancer treatment | |
| WO2022094132A1 (en) | A silicasome nanocarrier for metal-based drug delivery | |
| US20120171121A1 (en) | Rosette Nanotubes as Drug Delivery Agents | |
| Li et al. | Integrated and hyaluronic acid-coated mesoporous silica nanoparticles conjugated with cisplatin and chlorin e6 for combined chemo and photodynamic cancer therapy | |
| Mohammad-Jafari et al. | Cisplatin-based liposomal nanocarriers for drug delivery in lung cancer therapy: Recent progress and future outlooks | |
| CN109675048B (en) | A kind of anticancer prodrug liposome and artemisinin liposome nano-drug | |
| Kim et al. | In situ hypoxia modulating nano-catalase for amplifying DNA damage in radiation resistive colon tumors | |
| WO2024228631A1 (en) | A pharmaceutical composition comprising emetine and mitoxantrone for the prevention or treatment of mammary gland cancer and a liposome containing this composition | |
| US9878049B2 (en) | High drug loading system to co-deliver anticancer drugs and nucleic acids for cancer therapy | |
| EP3849616B1 (en) | Drug delivery sytem for platinum-based drugs | |
| JP2026515211A (en) | A pharmaceutical composition for the prevention or treatment of breast cancer, comprising emetine and mitoxantrone, and liposomes containing this composition. | |
| US20150306241A1 (en) | Copolymers for the delivery of drugs into cells | |
| EP3137069A1 (en) | Nanoparticle formulation containing farnesylthiosalicylic acid (salirasib) | |
| EP3060201A1 (en) | Polymer nanoparticles containing multiple agents and methods thereof | |
| CN109568599B (en) | A liposome-modified doxorubicin and doxorubicin-containing nanoparticles | |
| Ma et al. | An Engineered Iron-Based MOF for siRNA Delivery Targeting Chemotherapy-Resistant Triple-Negative Breast Cancer | |
| WO2024228630A1 (en) | A pharmaceutical composition comprising 17-aag and staurosporine for use in the prevention or treatment of cancer and diseases resulting from excessive cell proliferation and a polymer- lipid nanoparticle containing the composition | |
| Nguyen | Design and decoration of heparin on porous nanosilica via reversible disulfide linkages for controlled drug release | |
| Chen et al. | Multi-functional F127-grafted vitamin E succinate-modified liposomes for enhancing glioma therapy |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| STAA | Information on the status of an ep patent application or granted ep patent |
Free format text: STATUS: UNKNOWN |
|
| STAA | Information on the status of an ep patent application or granted ep patent |
Free format text: STATUS: THE INTERNATIONAL PUBLICATION HAS BEEN MADE |
|
| PUAI | Public reference made under article 153(3) epc to a published international application that has entered the european phase |
Free format text: ORIGINAL CODE: 0009012 |
|
| STAA | Information on the status of an ep patent application or granted ep patent |
Free format text: STATUS: REQUEST FOR EXAMINATION WAS MADE |
|
| 17P | Request for examination filed |
Effective date: 20251203 |
|
| AK | Designated contracting states |
Kind code of ref document: A1 Designated state(s): AL AT BE BG CH CY CZ DE DK EE ES FI FR GB GR HR HU IE IS IT LI LT LU LV MC ME MK MT NL NO PL PT RO RS SE SI SK SM TR |